[Pharmacology of spasticity. Does therapy remain in deep sleep?].
Noth
J
J
D000818:Animals; D001418:Baclofen / Q000009:adverse effects / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D003000:Clonidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004345:Drug Industry; D006801:Humans; D007278:Injections, Spinal; D009125:Muscle Relaxants, Central / Q000009:adverse effects / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects; D018080:Receptors, GABA-B / Q000187:drug effects; D012106:Research
D009125:Muscle Relaxants, Central; D018341:Receptors, Adrenergic, alpha-2; D018080:Receptors, GABA-B; C023754:tizanidine; D019274:Botulinum Toxins, Type A; D001418:Baclofen; D003000:Clonidine